mitoxantrone has been researched along with Liver Neoplasms in 79 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Liver Neoplasms: Tumors or cancer of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate the dose-limiting toxicities (DLTs) and determine the recommended doses in the Phase I part of the study, and to evaluate the efficacy and toxicity in the Phase II part, of continuous hepatic intra-arterial infusion therapy with 5-fluorouracil, mitoxantrone and cisplatin (FMP therapy) in patients with advanced hepatocellular carcinoma (HCC)." | 9.24 | A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma. ( Arai, Y; Furuse, J; Ikeda, M; Inaba, Y; Kobayashi, T; Mitsunaga, S; Morizane, C; Okusaka, T; Sato, Y; Ueno, H, 2017) |
| "The aim was to determine the recommended dose of combined chemotherapy with mitoxantrone and uracil/tegafur (Phase I part) and to clarify its efficacy and safety in patients with advanced hepatocellular carcinoma at the recommended dose (Phase II part)." | 9.15 | A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Suzuki, E; Ueno, H, 2011) |
| "Vinorelbine and mitoxantrone have both been demonstrated to have significant antitumor activity in patients with breast cancer." | 9.12 | Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer. ( Aravantinos, G; Bafaloukos, D; Fountzilas, G; Gogas, H; Kalofonos, HP; Koutras, A; Makatsoris, T; Mantzourani, M; Markopoulos, C; Onyenadum, A; Tzorakoelefterakis, E; Xiros, N, 2007) |
| "The aim of the current study was to evaluate the antitumor activity and toxicity of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) in chemotherapy-naive patients with metastatic hepatocellular carcinoma (HCC)." | 9.11 | A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. ( Ikeda, M; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H, 2005) |
| "A total of 260 women with measurable metastatic breast cancer fulfilling high-risk criteria, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either mitoxantrone 12 mg/m(2) or the combination of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) (FEC) every 3 weeks." | 9.10 | Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. ( Andreesen, R; Bodenstein, H; Clemens, M; Fehnle, K; Fischer, JT; Heidemann, E; Hirschmann, WD; Kaufmann, M; König, M; Mahlke, M; Oberhoff, C; Scharl, A; Schulze, M; Souchon, R; Stoeger, H, 2002) |
| "Mitoxantrone is an anthraquinone derivative that has demonstrated encouraging preclinical and clinical activity against a variety of human carcinoma cell lines and malignancies." | 9.07 | A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. ( Abbruzzese, J; Ajani, JA; Carrasco, CH; Charnsangavej, C; Jones, DV; Levin, B; Patt, YZ; Wallace, S, 1993) |
| "To investigate the effect of intra-arterial injection of mitoxantrone emulsified with ethiodized oil, forty-eight patients with hepatocellular carcinoma were evaluated." | 9.07 | [Clinical study on the effect of intra-arterial injection of mitoxantrone-lipiodol emulsion for hepatocellular carcinoma]. ( Hirayama, R; Ichikawa, W; Kawachi, Y; Mishima, Y; Miyanaga, T; Nihei, Z; Osanai, T; Sawai, S; Togo, S; Yamashita, T, 1994) |
| "Two hundred and twenty-four patients with advanced breast cancer were enrolled in a multicenter prospective randomized clinical study and received either doxorubicin (40 mg/m2), or epirubicin (40 mg/m2) or mitoxantrone (12 mg/m2) each combined with cyclophosphamide (600 mg/m2) i." | 9.06 | Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. ( Hartlapp, J; Heidemann, E; Hossfeld, D; Kunz, S; Neeser, E; Possinger, K; Schumacher, K; Steinke, B; von Ingersleben, G; Waldmann, R, 1990) |
| "In patients with advanced hepatocellular carcinoma (HCC), combination chemotherapy using 5- fluorouracil, cisplatin, and mitoxantrone (FMP) could achieve a response rate > 20%, but the beneficial effect was compromised by formidable adverse events." | 7.77 | Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. ( Chen, HC; Hsu, CL; Hung, CF; Lin, CC; Pan, KT; Sung, CM; Tseng, JH; Yeh, CT, 2011) |
| "We evaluated the anti-tumor efficacy and toxicity of 5-fluorouracil (5-FU), mitoxantrone, and cisplatin (FMP) in patients with advanced hepatocellular carcinoma (HCC), and conducted an analysis of the prognostic factors for response to such therapy and patient survival." | 7.72 | Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. ( Chang, HK; Chang, WC; Chen, JS; Liau, CT; Lin, YC; Yang, TS, 2004) |
| "A 60-year-old woman with her right breast cancer showing simultaneous and multiple liver metastases was initially treated with CEFT [cyclophosphamide (CPA), epirubicin (epi-ADM), 5-fluorouracil (5-FU), tamoxifen (TAM)]." | 7.70 | [A case of breast cancer with liver metastases responding remarkably to combination therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)]. ( Fujitake, S; Kataoka, S; Maeda, Y; Nozaki, H; Shimizu, M; Tohyama, M, 1999) |
| "Cyclic intra-arterial infusion chemotherapy using Mitoxantrone via reservoir system was prescribed for 8 patients with advanced hepatocellular carcinoma." | 7.69 | [Clinical study of cyclic intra-arterial chemotherapy using mitoxantrone for advanced hepatocellular carcinoma]. ( Harima, K; Kawa, S; Murata, T; Nagata, K; Nishida, T; Okuda, M; Oshima, T; Seki, Y; Tanaka, Y; Uda, M, 1994) |
| "The toxicity of escalating doses of liposome-complexed mitoxantrone (LCM) was evaluated in 22 women with histological/cytological diagnosis of metastatic breast cancer (21 pts) or adenocarcinoma of unknown primary origin (1 pt)." | 7.68 | Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. ( Pestalozzi, B; Sauter, C; Schwendener, R, 1992) |
| "A total of 20 patients with histologically proven primary hepatocellular carcinoma (PHC) received mitoxantrone IV at a dose of 10-16 mg/m2 every 3 weeks." | 7.67 | Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection. ( Lai, KH; Lee, SD; Lin, HC; Lin, HJ; Lo, GH; Ng, WW; Tam, TN; Teng, HC; Tsai, YT; Wu, JC, 1989) |
| "1 years) and 1 male (71 years) with histologically verified metastasizing breast cancer were submitted to mitoxantrone therapy." | 7.67 | [Mitoxantrone in the primary treatment of metastasizing breast cancer]. ( Dittrich, C; Dudczak, R; Lenzhofer, R; Moser, K; Pirker, P; Rainer, H; Schuster, R, 1984) |
| "Mitoxantrone was given to 19 patients with liver metastases from breast cancer and biochemical evidence of liver dysfunction." | 7.67 | Phase II study of mitoxantrone for liver metastases from breast cancer. ( Coleman, RE; O'Reilly, SM; Rubens, RD, 1989) |
| "Twenty-three patients (16 male, seven female) with hepatocellular carcinoma (HCC) were treated by hepatic arterial infusion (HAI) of mitoxantrone every 4 weeks." | 7.67 | Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. ( Blackstein, ME; Evans, WK; Fine, S; Habal, F; Heathcote, J; Kutas, G; Langer, B; Pritchard, KI; Shepherd, FA; Taylor, B, 1987) |
| "In this study, we used hepatocellular carcinoma (HCC) cells as models to identify cytotoxic compounds by HTS." | 5.56 | High-throughput screening identified mitoxantrone to induce death of hepatocellular carcinoma cells with autophagy involvement. ( Guo, G; He, X; Li, J; Lin, Y; Liu, J; Xie, B; Zhang, X, 2020) |
| "Twenty patients with unresectable hepatoma, recurrent hepatoma or metastatic liver cancer were treated by intra-hepatic arterial injection of mitoxantrone, and its effectiveness and side effects were studied." | 5.29 | [Effects of intra-hepatic arterial injection of mitoxantrone for hepatocellular carcinoma]. ( Hiraki, S; Maeda, Y; Nakashima, K; Nishida, M; Oka, M; Suzuki, T; Takao, K; Takao, T, 1996) |
| "Patients affected by hepatocellular carcinoma (HCC) with unfavorable prognostic factors have limited therapeutic options due to moderate responsiveness to chemotherapeutic agents and lack of compliance with such treatments." | 5.28 | Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors. ( Bajetta, E; Colleoni, M; de Braud, F; Di Bartolomeo, M; Nole, F, 1992) |
| "The aim of this study was to investigate the dose-limiting toxicities (DLTs) and determine the recommended doses in the Phase I part of the study, and to evaluate the efficacy and toxicity in the Phase II part, of continuous hepatic intra-arterial infusion therapy with 5-fluorouracil, mitoxantrone and cisplatin (FMP therapy) in patients with advanced hepatocellular carcinoma (HCC)." | 5.24 | A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma. ( Arai, Y; Furuse, J; Ikeda, M; Inaba, Y; Kobayashi, T; Mitsunaga, S; Morizane, C; Okusaka, T; Sato, Y; Ueno, H, 2017) |
| "The aim was to determine the recommended dose of combined chemotherapy with mitoxantrone and uracil/tegafur (Phase I part) and to clarify its efficacy and safety in patients with advanced hepatocellular carcinoma at the recommended dose (Phase II part)." | 5.15 | A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Suzuki, E; Ueno, H, 2011) |
| "Vinorelbine and mitoxantrone have both been demonstrated to have significant antitumor activity in patients with breast cancer." | 5.12 | Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer. ( Aravantinos, G; Bafaloukos, D; Fountzilas, G; Gogas, H; Kalofonos, HP; Koutras, A; Makatsoris, T; Mantzourani, M; Markopoulos, C; Onyenadum, A; Tzorakoelefterakis, E; Xiros, N, 2007) |
| "The aim of the current study was to evaluate the antitumor activity and toxicity of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) in chemotherapy-naive patients with metastatic hepatocellular carcinoma (HCC)." | 5.11 | A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. ( Ikeda, M; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H, 2005) |
| "A total of 260 women with measurable metastatic breast cancer fulfilling high-risk criteria, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either mitoxantrone 12 mg/m(2) or the combination of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) (FEC) every 3 weeks." | 5.10 | Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. ( Andreesen, R; Bodenstein, H; Clemens, M; Fehnle, K; Fischer, JT; Heidemann, E; Hirschmann, WD; Kaufmann, M; König, M; Mahlke, M; Oberhoff, C; Scharl, A; Schulze, M; Souchon, R; Stoeger, H, 2002) |
| "Mitoxantrone is an anthraquinone derivative that has demonstrated encouraging preclinical and clinical activity against a variety of human carcinoma cell lines and malignancies." | 5.07 | A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. ( Abbruzzese, J; Ajani, JA; Carrasco, CH; Charnsangavej, C; Jones, DV; Levin, B; Patt, YZ; Wallace, S, 1993) |
| "To investigate the effect of intra-arterial injection of mitoxantrone emulsified with ethiodized oil, forty-eight patients with hepatocellular carcinoma were evaluated." | 5.07 | [Clinical study on the effect of intra-arterial injection of mitoxantrone-lipiodol emulsion for hepatocellular carcinoma]. ( Hirayama, R; Ichikawa, W; Kawachi, Y; Mishima, Y; Miyanaga, T; Nihei, Z; Osanai, T; Sawai, S; Togo, S; Yamashita, T, 1994) |
| "Two hundred and twenty-four patients with advanced breast cancer were enrolled in a multicenter prospective randomized clinical study and received either doxorubicin (40 mg/m2), or epirubicin (40 mg/m2) or mitoxantrone (12 mg/m2) each combined with cyclophosphamide (600 mg/m2) i." | 5.06 | Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. ( Hartlapp, J; Heidemann, E; Hossfeld, D; Kunz, S; Neeser, E; Possinger, K; Schumacher, K; Steinke, B; von Ingersleben, G; Waldmann, R, 1990) |
| "CT26 murine colorectal cancer cells were treated with physiologic levels of the potent inducer of immunogenic cell death mitoxantrone (MTX)." | 3.91 | Vaccination With Mitoxantrone-Treated Primary Colon Cancer Cells Enhances Tumor-Infiltrating Lymphocytes and Clinical Responses in Colorectal Liver Metastases. ( Kunda, NM; Maker, AV; Prabhakar, BS; Qiao, G; Qin, J; Tulla, K, 2019) |
| "In patients with advanced hepatocellular carcinoma (HCC), combination chemotherapy using 5- fluorouracil, cisplatin, and mitoxantrone (FMP) could achieve a response rate > 20%, but the beneficial effect was compromised by formidable adverse events." | 3.77 | Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. ( Chen, HC; Hsu, CL; Hung, CF; Lin, CC; Pan, KT; Sung, CM; Tseng, JH; Yeh, CT, 2011) |
| "We established epirubicin (EPI)--and mitoxantrone (MIT)--resistant cell lines (HLE-EPI and HLE-MIT) from the human hepatocellular carcinoma cell line (HLE)." | 3.74 | N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma. ( Deguchi, K; Hamaguchi, J; Kamiyama, N; Kamiyama, T; Kudo, T; Nakagawa, H; Nakagawa, T; Nakanishi, K; Nishimura, S; Takahashi, M; Todo, S; Yokoo, H, 2007) |
| "We evaluated the anti-tumor efficacy and toxicity of 5-fluorouracil (5-FU), mitoxantrone, and cisplatin (FMP) in patients with advanced hepatocellular carcinoma (HCC), and conducted an analysis of the prognostic factors for response to such therapy and patient survival." | 3.72 | Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. ( Chang, HK; Chang, WC; Chen, JS; Liau, CT; Lin, YC; Yang, TS, 2004) |
| "A 60-year-old woman with her right breast cancer showing simultaneous and multiple liver metastases was initially treated with CEFT [cyclophosphamide (CPA), epirubicin (epi-ADM), 5-fluorouracil (5-FU), tamoxifen (TAM)]." | 3.70 | [A case of breast cancer with liver metastases responding remarkably to combination therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)]. ( Fujitake, S; Kataoka, S; Maeda, Y; Nozaki, H; Shimizu, M; Tohyama, M, 1999) |
| "Cyclic intra-arterial infusion chemotherapy using Mitoxantrone via reservoir system was prescribed for 8 patients with advanced hepatocellular carcinoma." | 3.69 | [Clinical study of cyclic intra-arterial chemotherapy using mitoxantrone for advanced hepatocellular carcinoma]. ( Harima, K; Kawa, S; Murata, T; Nagata, K; Nishida, T; Okuda, M; Oshima, T; Seki, Y; Tanaka, Y; Uda, M, 1994) |
| "This paper reports the result of an experiment on the anticarcinogenic effect of liver targeted drug delivery system-mitoxantrone-polybutylcyanoacrylate-nanospheres (DHAQ-PBCA-NS) by using a model of heterotopic and orthotopic transplantation of human hepatocellular carcinoma (HCC) in nude mice." | 3.68 | [An observation of the anticarcinogenic effect of mitoxantrone-polybutylcyanoacrylate-nanosperes]. ( Bai, S; Hou, S; Liao, G; Zhang, X; Zhang, Z, 1993) |
| "A 61-year-old man received systemic mitoxantrone chemotherapy following transarterial embolization of a large hepatocellular carcinoma with extensive intrahepatic, lung and bone metastases." | 3.68 | Changes in mode of response to chemotherapy for hepatocellular carcinoma induced by transarterial embolization. A case report. ( Moriyama, N; Okada, S; Okazaki, N; Shimada, Y; Takayasu, K; Yoshida, T; Yoshino, M, 1991) |
| "The toxicity of escalating doses of liposome-complexed mitoxantrone (LCM) was evaluated in 22 women with histological/cytological diagnosis of metastatic breast cancer (21 pts) or adenocarcinoma of unknown primary origin (1 pt)." | 3.68 | Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. ( Pestalozzi, B; Sauter, C; Schwendener, R, 1992) |
| "1 years) and 1 male (71 years) with histologically verified metastasizing breast cancer were submitted to mitoxantrone therapy." | 3.67 | [Mitoxantrone in the primary treatment of metastasizing breast cancer]. ( Dittrich, C; Dudczak, R; Lenzhofer, R; Moser, K; Pirker, P; Rainer, H; Schuster, R, 1984) |
| "A total of 20 patients with histologically proven primary hepatocellular carcinoma (PHC) received mitoxantrone IV at a dose of 10-16 mg/m2 every 3 weeks." | 3.67 | Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection. ( Lai, KH; Lee, SD; Lin, HC; Lin, HJ; Lo, GH; Ng, WW; Tam, TN; Teng, HC; Tsai, YT; Wu, JC, 1989) |
| "Mitoxantrone was given to 19 patients with liver metastases from breast cancer and biochemical evidence of liver dysfunction." | 3.67 | Phase II study of mitoxantrone for liver metastases from breast cancer. ( Coleman, RE; O'Reilly, SM; Rubens, RD, 1989) |
| "Twenty-three patients (16 male, seven female) with hepatocellular carcinoma (HCC) were treated by hepatic arterial infusion (HAI) of mitoxantrone every 4 weeks." | 3.67 | Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. ( Blackstein, ME; Evans, WK; Fine, S; Habal, F; Heathcote, J; Kutas, G; Langer, B; Pritchard, KI; Shepherd, FA; Taylor, B, 1987) |
| "Unresectable hepatocellular carcinoma is related to a poor prognosis." | 2.68 | Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma. ( Colleoni, M; Liessi, G; Manente, P; Mastrapasqua, G; Nelli, P; Pancheri, F; Sgarbossa, G; Vicario, G, 1997) |
| "every 3 weeks to 15 patients with hepatocellular carcinoma." | 2.66 | Human lymphoblastoid interferon does not increase survival when added to mitozantrone in the treatment of hepatocellular carcinomas. ( Brook, MG; Dunk, AA; Goh, C; Lever, AM; McDonald, JA; Thomas, HC, 1987) |
| "Patients with hepatocellular carcinoma (HCC) frequently show early recurrence even after hepatic resection and local ablation therapy." | 2.42 | [Chemotherapy for hepatocellular carcinoma]. ( Ikeda, M; Okusaka, T; Ueno, H, 2004) |
| "The vast majority of primary hepatocellular cancer is hepatocellular carcinomas (HCCs)." | 1.62 | miR-130-3p Promotes MTX-Induced Immune Killing of Hepatocellular Carcinoma Cells by Targeting EPHB4. ( Jia, M; Shao, L; Ye, Q, 2021) |
| "The Barcelona Clinic Liver Cancer (BCLC) staging system is commonly used to classify hepatocellular carcinoma (HCC) patients." | 1.56 | Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. ( Czauderna, C; Galle, PR; Heil, E; Heinrich, B; Heinrich, S; Kloeckner, R; Koch, S; Marquardt, JU; Philippe P Diggs, L; Schmidtmann, I; Sprinzl, M; Weinmann, A; Wörns, MA, 2020) |
| "In this study, we used hepatocellular carcinoma (HCC) cells as models to identify cytotoxic compounds by HTS." | 1.56 | High-throughput screening identified mitoxantrone to induce death of hepatocellular carcinoma cells with autophagy involvement. ( Guo, G; He, X; Li, J; Lin, Y; Liu, J; Xie, B; Zhang, X, 2020) |
| "Hepatocellular carcinoma is the third most common cause of cancer-related deaths worldwide." | 1.42 | Dual properties of hispidulin: antiproliferative effects on HepG2 cancer cells and selective inhibition of ABCG2 transport activity. ( Di Pietro, A; Guterres, FA; Martinez, GR; Rocha, ME; Scoparo, CT; Valdameri, G; Winnischofer, SM; Worfel, PR, 2015) |
| " The pharmacokinetic study in rats showed that LPG significantly prolonged the circulation time and enhanced the bioavailability of MX." | 1.38 | Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells. ( Fan, R; Gan, Y; Guo, S; Li, F; Yu, M; Zhang, X; Zhu, C, 2012) |
| "We report a patient suffering from acute nonlymphocytic leukemia (ANLL) 3 years after treatment for stage IV ovarian cancer began." | 1.31 | Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer. ( Fujii, S; Fukushi, Y; Futagami, M; Higuchi, T; Saito, Y; Sakamoto, T; Sato, S; Takami, H; Yokoyama, Y, 2000) |
| "Out of 87 patients with hepatocellular carcinoma who underwent an operation in the past 7 years in our hospital, 60 survived for more than 1 year and were enrolled in our study." | 1.30 | [The effect of hepatic arterial infusion chemotherapy on the prognosis after hepatectomy for hepatocellular carcinoma]. ( Hasegawa, M; Koyama, T; Manabe, K; Takagi, K, 1998) |
| "Twenty patients with unresectable hepatoma, recurrent hepatoma or metastatic liver cancer were treated by intra-hepatic arterial injection of mitoxantrone, and its effectiveness and side effects were studied." | 1.29 | [Effects of intra-hepatic arterial injection of mitoxantrone for hepatocellular carcinoma]. ( Hiraki, S; Maeda, Y; Nakashima, K; Nishida, M; Oka, M; Suzuki, T; Takao, K; Takao, T, 1996) |
| "Patients affected by hepatocellular carcinoma (HCC) with unfavorable prognostic factors have limited therapeutic options due to moderate responsiveness to chemotherapeutic agents and lack of compliance with such treatments." | 1.28 | Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors. ( Bajetta, E; Colleoni, M; de Braud, F; Di Bartolomeo, M; Nole, F, 1992) |
| "We applied it for a case of hepatocellular carcinoma with good result." | 1.28 | [Successful preparation of mitoxantrone emulsion containing non-ionic contrast medium]. ( Hirayama, R; Ichikawa, W; Kawachi, Y; Mishima, Y; Nihei, Z; Sawai, S; Tamaru, H; Uetake, H; Yamashita, T, 1992) |
| "The overlap between hepatocellular carcinoma and cirrhosis, however, was such as to severely limit any value of the enzyme as a diagnostic test." | 1.28 | Serum and tissue alpha-L-fucosidase activity in the pre-clinical and clinical stages of hepatocellular carcinoma. ( Du, MQ; Hutchinson, WL; Johnson, PJ; Williams, R, 1991) |
| " This suggests that mitoxantrone is oxidised to a toxic intermediate by the MFO system." | 1.28 | The role of reductive and oxidative metabolism in the toxicity of mitoxantrone, adriamycin and menadione in human liver derived Hep G2 hepatoma cells. ( Duthie, SJ; Grant, MH, 1989) |
| "Thirty-five patients with hepatocellular carcinoma (HCC) have been treated with the Anthracenedione derivative, Mitozantrone." | 1.27 | Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study. ( Dunk, AA; Johnson, PJ; Lok, AS; Melia, W; Murray-Lyon, I; Scott, SC; Thomas, HC; Williams, R, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (22.78) | 18.7374 |
| 1990's | 29 (36.71) | 18.2507 |
| 2000's | 18 (22.78) | 29.6817 |
| 2010's | 11 (13.92) | 24.3611 |
| 2020's | 3 (3.80) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Q | 1 |
| Zhai, Y | 1 |
| Luo, W | 1 |
| Zhu, Z | 2 |
| Zhang, X | 5 |
| Xie, S | 1 |
| Hong, C | 1 |
| Wang, Y | 1 |
| Su, Y | 1 |
| Zhao, J | 1 |
| Wang, C | 1 |
| Xie, B | 1 |
| He, X | 1 |
| Guo, G | 1 |
| Li, J | 1 |
| Liu, J | 2 |
| Lin, Y | 1 |
| Heinrich, S | 1 |
| Sprinzl, M | 1 |
| Schmidtmann, I | 1 |
| Heil, E | 1 |
| Koch, S | 1 |
| Czauderna, C | 1 |
| Heinrich, B | 1 |
| Philippe P Diggs, L | 1 |
| Wörns, MA | 1 |
| Kloeckner, R | 1 |
| Galle, PR | 1 |
| Marquardt, JU | 1 |
| Weinmann, A | 1 |
| Shao, L | 1 |
| Ye, Q | 1 |
| Jia, M | 1 |
| Ikeda, M | 5 |
| Okusaka, T | 5 |
| Sato, Y | 1 |
| Furuse, J | 2 |
| Mitsunaga, S | 2 |
| Ueno, H | 5 |
| Morizane, C | 4 |
| Inaba, Y | 1 |
| Kobayashi, T | 1 |
| Arai, Y | 1 |
| Liu, D | 1 |
| Hu, Y | 1 |
| Guo, Y | 1 |
| Lu, B | 1 |
| Wang, X | 2 |
| Huang, Y | 1 |
| Han, Y | 1 |
| An, Y | 1 |
| Jia, G | 1 |
| He, C | 1 |
| Ding, Y | 1 |
| Tang, Q | 1 |
| Qin, J | 1 |
| Kunda, NM | 1 |
| Qiao, G | 1 |
| Tulla, K | 1 |
| Prabhakar, BS | 1 |
| Maker, AV | 1 |
| Kumar, S | 1 |
| Sharma, P | 1 |
| Kumar, D | 1 |
| Chakraborty, G | 1 |
| Gorain, M | 1 |
| Kundu, GC | 1 |
| Scoparo, CT | 1 |
| Valdameri, G | 1 |
| Worfel, PR | 1 |
| Guterres, FA | 1 |
| Martinez, GR | 1 |
| Winnischofer, SM | 1 |
| Di Pietro, A | 1 |
| Rocha, ME | 1 |
| Kojima, Y | 1 |
| Iwasa, S | 1 |
| Hagihara, A | 1 |
| Zhou, Q | 1 |
| Sun, X | 1 |
| Zeng, L | 1 |
| Zhang, Z | 3 |
| Suzuki, E | 1 |
| Ishii, H | 1 |
| Nakachi, K | 1 |
| Yeh, CT | 2 |
| Chen, HC | 1 |
| Sung, CM | 1 |
| Hsu, CL | 1 |
| Lin, CC | 2 |
| Pan, KT | 1 |
| Tseng, JH | 1 |
| Hung, CF | 1 |
| Liang, KH | 1 |
| Guo, S | 1 |
| Fan, R | 1 |
| Yu, M | 1 |
| Li, F | 1 |
| Zhu, C | 1 |
| Gan, Y | 1 |
| Heidemann, E | 2 |
| Stoeger, H | 1 |
| Souchon, R | 1 |
| Hirschmann, WD | 1 |
| Bodenstein, H | 1 |
| Oberhoff, C | 1 |
| Fischer, JT | 1 |
| Schulze, M | 1 |
| Clemens, M | 1 |
| Andreesen, R | 1 |
| Mahlke, M | 1 |
| König, M | 1 |
| Scharl, A | 1 |
| Fehnle, K | 1 |
| Kaufmann, M | 1 |
| Yang, TS | 1 |
| Chang, HK | 1 |
| Chen, JS | 1 |
| Lin, YC | 1 |
| Liau, CT | 1 |
| Chang, WC | 1 |
| Takezako, Y | 1 |
| Dillman, RO | 1 |
| Barth, NM | 1 |
| VanderMolen, LA | 1 |
| Allen, K | 1 |
| Beutel, LD | 1 |
| Chico, S | 1 |
| Akimoto, M | 1 |
| Yoshikawa, M | 1 |
| Ebara, M | 1 |
| Sato, T | 1 |
| Fukuda, H | 1 |
| Kondo, F | 1 |
| Saisho, H | 1 |
| Enoki, T | 1 |
| Kitada, K | 1 |
| Harada, E | 1 |
| Noshima, S | 1 |
| Hamano, K | 1 |
| Kudo, T | 1 |
| Nakagawa, H | 1 |
| Takahashi, M | 1 |
| Hamaguchi, J | 1 |
| Kamiyama, N | 1 |
| Yokoo, H | 1 |
| Nakanishi, K | 1 |
| Nakagawa, T | 1 |
| Kamiyama, T | 1 |
| Deguchi, K | 1 |
| Nishimura, S | 1 |
| Todo, S | 1 |
| Onyenadum, A | 1 |
| Gogas, H | 1 |
| Markopoulos, C | 1 |
| Bafaloukos, D | 1 |
| Aravantinos, G | 1 |
| Mantzourani, M | 1 |
| Koutras, A | 1 |
| Tzorakoelefterakis, E | 1 |
| Xiros, N | 1 |
| Makatsoris, T | 1 |
| Fountzilas, G | 1 |
| Kalofonos, HP | 1 |
| Lenzhofer, R | 1 |
| Rainer, H | 1 |
| Schuster, R | 1 |
| Pirker, P | 1 |
| Dudczak, R | 1 |
| Dittrich, C | 1 |
| Moser, K | 1 |
| Falkson, G | 3 |
| Coetzer, BJ | 3 |
| Terblanche, AP | 1 |
| Bedikian, AY | 1 |
| Stroehlein, J | 1 |
| Korinek, J | 1 |
| Karlin, D | 1 |
| Valdivieso, M | 1 |
| Bodey, GP | 1 |
| Ichikawa, W | 2 |
| Togo, S | 1 |
| Osanai, T | 1 |
| Miyanaga, T | 1 |
| Sawai, S | 2 |
| Yamashita, T | 2 |
| Kawachi, Y | 2 |
| Nihei, Z | 2 |
| Hirayama, R | 2 |
| Mishima, Y | 2 |
| Kobayashi, J | 1 |
| Kubota, K | 1 |
| Ishikawa, H | 1 |
| Asaumi, S | 1 |
| Iwanami, K | 1 |
| Matsumoto, H | 1 |
| Kawashima, K | 1 |
| Yokoe, T | 2 |
| Iino, Y | 2 |
| Morishita, Y | 2 |
| Zhang, ZR | 1 |
| Liao, GT | 1 |
| Hou, SX | 1 |
| Murata, T | 2 |
| Uda, M | 1 |
| Nagata, K | 2 |
| Harima, K | 1 |
| Nishida, T | 1 |
| Kawa, S | 1 |
| Oshima, T | 1 |
| Tanaka, Y | 2 |
| Okuda, M | 1 |
| Seki, Y | 1 |
| Liao, G | 2 |
| Hou, S | 2 |
| Bai, S | 2 |
| Xie, C | 1 |
| Cherqui, D | 2 |
| Piedbois, P | 2 |
| Pierga, JY | 1 |
| Duvoux, C | 2 |
| Vavasseur, D | 1 |
| Tran Van-Nhieu, J | 1 |
| LeBourgeois, JP | 1 |
| Julien, M | 2 |
| Fagniez, PL | 1 |
| Dhumeaux, D | 1 |
| Mewes, K | 1 |
| Blanz, J | 1 |
| Ehninger, G | 1 |
| Gebhardt, R | 1 |
| Zeller, KP | 1 |
| Colleoni, M | 3 |
| Buzzoni, R | 1 |
| Bajetta, E | 2 |
| Bochicchio, AM | 1 |
| Bartoli, C | 1 |
| Audisio, R | 1 |
| Bonfanti, G | 1 |
| Nolè, F | 2 |
| Jones, DV | 1 |
| Patt, YZ | 1 |
| Ajani, JA | 1 |
| Abbruzzese, J | 1 |
| Carrasco, CH | 1 |
| Charnsangavej, C | 1 |
| Levin, B | 1 |
| Wallace, S | 1 |
| Aoyagi, H | 1 |
| Maemura, M | 1 |
| Sugamata, N | 1 |
| Takai, Y | 1 |
| Horiguchi, J | 1 |
| Ishida, T | 1 |
| Görich, J | 1 |
| Brensing, KA | 1 |
| Kunze, V | 1 |
| Sokiranski, R | 1 |
| Rilinger, N | 1 |
| Müller-Miny, H | 1 |
| Brambs, HJ | 1 |
| Link, KH | 6 |
| Pillasch, J | 5 |
| Weindel, M | 2 |
| Leder, G | 4 |
| Beger, HG | 6 |
| Hiraki, S | 1 |
| Nishida, M | 1 |
| Maeda, Y | 2 |
| Nakashima, K | 1 |
| Takao, K | 1 |
| Takao, T | 1 |
| Oka, M | 1 |
| Suzuki, T | 1 |
| Liessi, G | 1 |
| Mastrapasqua, G | 1 |
| Nelli, P | 1 |
| Vicario, G | 1 |
| Sgarbossa, G | 1 |
| Pancheri, F | 1 |
| Manente, P | 1 |
| Kornmann, M | 5 |
| Lenz, HJ | 1 |
| Metzger, R | 1 |
| Butzer, U | 3 |
| Leder, GH | 2 |
| Safi, F | 1 |
| Danenberg, KD | 2 |
| Danenberg, PV | 2 |
| Takagi, K | 1 |
| Koyama, T | 1 |
| Hasegawa, M | 1 |
| Manabe, K | 1 |
| Nasu, R | 1 |
| Kimura, H | 1 |
| Uokawa, K | 1 |
| Akagi, K | 1 |
| Staib, L | 2 |
| Gansauge, F | 2 |
| Pillasch, AF | 1 |
| Sunelaitis, E | 3 |
| Schatz, M | 2 |
| Pressmar, J | 1 |
| Fujitake, S | 1 |
| Shimizu, M | 1 |
| Nozaki, H | 1 |
| Tohyama, M | 1 |
| Kataoka, S | 1 |
| Bashey, A | 1 |
| Corringham, S | 1 |
| Garrett, J | 1 |
| Lane, TA | 1 |
| Gilpin, EA | 1 |
| Corringham, RE | 1 |
| Law, P | 1 |
| Ho, AD | 1 |
| Yokoyama, Y | 1 |
| Futagami, M | 1 |
| Fukushi, Y | 1 |
| Sakamoto, T | 1 |
| Higuchi, T | 1 |
| Fujii, S | 1 |
| Sato, S | 1 |
| Takami, H | 1 |
| Saito, Y | 1 |
| Salonga, D | 1 |
| Eilber, FC | 1 |
| Rosen, G | 1 |
| Forscher, C | 1 |
| Nelson, SD | 1 |
| Dorey, F | 1 |
| Eilber, FR | 1 |
| Carlson, LE | 1 |
| Koski, T | 1 |
| Glück, S | 1 |
| Formentini, A | 1 |
| Auerbach, M | 1 |
| Elias, EG | 1 |
| Orford, J | 1 |
| Di Bartolomeo, M | 1 |
| de Braud, F | 1 |
| Uetake, H | 1 |
| Tamaru, H | 1 |
| Mathieu, D | 1 |
| Le Péchoux, C | 1 |
| Lauzet, JY | 1 |
| Métreau, JM | 1 |
| Rotman, N | 1 |
| Charlotte, F | 1 |
| Okada, S | 2 |
| Okazaki, N | 3 |
| Nose, H | 1 |
| Yoshimori, M | 1 |
| Aoki, K | 1 |
| Pestalozzi, B | 1 |
| Schwendener, R | 1 |
| Sauter, C | 1 |
| Yoshida, T | 2 |
| Yoshino, M | 2 |
| Shimada, Y | 2 |
| Moriyama, N | 1 |
| Takayasu, K | 1 |
| Hutchinson, WL | 1 |
| Johnson, PJ | 2 |
| Du, MQ | 1 |
| Williams, R | 2 |
| Steinke, B | 1 |
| Hartlapp, J | 1 |
| Schumacher, K | 1 |
| Possinger, K | 1 |
| Kunz, S | 1 |
| Neeser, E | 1 |
| von Ingersleben, G | 1 |
| Hossfeld, D | 1 |
| Waldmann, R | 1 |
| Lai, KH | 1 |
| Tsai, YT | 1 |
| Lee, SD | 1 |
| Ng, WW | 1 |
| Teng, HC | 1 |
| Tam, TN | 1 |
| Lo, GH | 1 |
| Lin, HC | 1 |
| Lin, HJ | 1 |
| Wu, JC | 1 |
| Duthie, SJ | 2 |
| Grant, MH | 2 |
| O'Reilly, SM | 1 |
| Coleman, RE | 1 |
| Rubens, RD | 1 |
| McAleer, JJ | 1 |
| Dickey, W | 1 |
| Clarke, R | 1 |
| Johnston, GW | 1 |
| Callender, ME | 1 |
| Ryan, LM | 1 |
| Johnson, LA | 1 |
| Simson, IW | 1 |
| Carbone, PP | 1 |
| Creech, RH | 1 |
| Schutt, AJ | 1 |
| Ohkura, H | 1 |
| Miyamoto, K | 1 |
| Brook, MG | 1 |
| Dunk, AA | 2 |
| McDonald, JA | 1 |
| Lever, AM | 1 |
| Goh, C | 1 |
| Thomas, HC | 2 |
| Scott, SC | 1 |
| Melia, W | 1 |
| Lok, AS | 1 |
| Murray-Lyon, I | 1 |
| Shepherd, FA | 1 |
| Evans, WK | 1 |
| Blackstein, ME | 1 |
| Fine, S | 1 |
| Heathcote, J | 1 |
| Langer, B | 1 |
| Taylor, B | 1 |
| Habal, F | 1 |
| Kutas, G | 1 |
| Pritchard, KI | 1 |
| Bai, SH | 1 |
| Xu, G | 1 |
| Tang, P | 1 |
| Chen, XH | 1 |
| Büyükünal, E | 1 |
| Derman, U | 1 |
| Serdengecti, S | 1 |
| Berkarda, B | 1 |
| Davis, RB | 1 |
| Van Echo, DA | 1 |
| Leone, LA | 1 |
| Henderson, ES | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MITOXANTRONE (N) VS. 5-FLUOROURACIL, EPIRUBICIN AND CYCLOPHOSPHAMIDE AS FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC BREAST CANCER AND AN UNFAVORABLE PROGNOSIS[NCT00002544] | Phase 3 | 300 participants (Anticipated) | Interventional | 1993-05-31 | Completed | ||
| Human Liver Explants for HIF-1 Alpha- Analysis/Comparison[NCT00866957] | 180 participants (Actual) | Observational | 2006-02-28 | Completed | |||
| A Randomized Phase II Trial of Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma or Who Are Unfit for Standard Therapy[NCT01097083] | Phase 2 | 20 participants | Interventional | 2010-04-30 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for mitoxantrone and Liver Neoplasms
| Article | Year |
|---|---|
[Chemotherapy for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Clinical Trial | 2004 |
Mitoxantrone, 5-FU + folinic acid, mitomycin C for regional chemotherapy of malignant liver tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Reg | 1996 |
Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug | 1999 |
21 trials available for mitoxantrone and Liver Neoplasms
| Article | Year |
|---|---|
A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters; C | 2017 |
A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Female; | 2009 |
A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carci | 2011 |
Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Breast | 2002 |
A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2005 |
High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carbo | 2005 |
Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brai | 2007 |
[Clinical study on the effect of intra-arterial injection of mitoxantrone-lipiodol emulsion for hepatocellular carcinoma].
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Hepatic Artery; Humans; Injection | 1994 |
A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Administration Schedule | 1993 |
A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver.
Topics: Adult; Aged; Carcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Female; Hepatic Artery; Hum | 1993 |
Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular; | 1997 |
Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomar | 1997 |
[Effect on hepatic function of hepatic artery infusion chemotherapy using epirubicin and mitoxantrone for advanced hepatocellular carcinoma].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration S | 1998 |
Regional chemotherapy directed by individual chemosensitivity testing in vitro: a prospective decision-aiding trial.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; | 1996 |
A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin | 2000 |
Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorour | 2000 |
Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2001 |
Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1990 |
A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Evaluatio | 1987 |
Human lymphoblastoid interferon does not increase survival when added to mitozantrone in the treatment of hepatocellular carcinomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1987 |
A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clini | 1987 |
55 other studies available for mitoxantrone and Liver Neoplasms
| Article | Year |
|---|---|
Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Aspirin; Car | 2016 |
High-throughput screening identified mitoxantrone to induce death of hepatocellular carcinoma cells with autophagy involvement.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Proliferation; Dose-Response Rela | 2020 |
Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2020 |
miR-130-3p Promotes MTX-Induced Immune Killing of Hepatocellular Carcinoma Cells by Targeting EPHB4.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; MicroRNAs; Mitoxantrone; Recep | 2021 |
Mycoplasma-associated multidrug resistance of hepatocarcinoma cells requires the interaction of P37 and Annexin A2.
Topics: Adaptor Proteins, Signal Transducing; Annexin A2; Anti-Bacterial Agents; Antineoplastic Agents; Azit | 2017 |
Theranostic micelles based on upconversion nanoparticles for dual-modality imaging and photodynamic therapy in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Delivery Systems; Epithelial Cell Adhesio | 2018 |
Vaccination With Mitoxantrone-Treated Primary Colon Cancer Cells Enhances Tumor-Infiltrating Lymphocytes and Clinical Responses in Colorectal Liver Metastases.
Topics: Animals; Antineoplastic Agents; Cancer Vaccines; Cell Cycle Checkpoints; Cell Line, Tumor; Colorecta | 2019 |
Functional characterization of stromal osteopontin in melanoma progression and metastasis.
Topics: Animals; Carcinogenesis; Cell Communication; Cell Proliferation; Cell Separation; Disease Progressio | 2013 |
Dual properties of hispidulin: antiproliferative effects on HepG2 cancer cells and selective inhibition of ABCG2 transport activity.
Topics: Animals; Antioxidants; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Bindi | 2015 |
Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy | 2008 |
Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinical Protocols; Dise | 2011 |
GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, | 2011 |
Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Multiple; Humans; Liposomes; | 2012 |
Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; F | 2004 |
Relationship between therapeutic efficacy of arterial infusion chemotherapy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinoma.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Carcinoma, Hepatocellular; Epi | 2006 |
[A case of multiple lung metastases of hepatocellular carcinoma after resection of liver and tumor thrombi in the inferior vena cava responding to chemotherapy using 5-FU, mitoxantrone and CDDP].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cispl | 2007 |
N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma.
Topics: Antibiotics, Antineoplastic; Carbohydrate Sequence; Carcinoma, Hepatocellular; Down-Regulation; Drug | 2007 |
[Mitoxantrone in the primary treatment of metastasizing breast cancer].
Topics: Aged; Alopecia; Anthraquinones; Brain Neoplasms; Breast Neoplasms; Drug Tolerance; Electrocardiograp | 1984 |
Phase II trial of mitoxantrone in patients with primary liver cancer.
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leu | 1984 |
Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with upper gastrointestinal tumors. A preliminary report.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukocyte Count | 1983 |
[A case of recurrent breast cancer responding to combination therapy with mitoxantrone (MIT), 5'-deoxy-5-fluorouridine (5'-DFUR) and medroxyprogesterone acetate (MPA)].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1994 |
[Study on mitoxantrone polycyanoacrylate nanospheres].
Topics: Animals; Cyanoacrylates; Drug Carriers; Humans; Liver Neoplasms; Mice; Mice, Nude; Microspheres; Mit | 1994 |
[Clinical study of cyclic intra-arterial chemotherapy using mitoxantrone for advanced hepatocellular carcinoma].
Topics: Aged; Carcinoma, Hepatocellular; Drug Administration Schedule; Hepatic Artery; Humans; Infusion Pump | 1994 |
[An observation of the anticarcinogenic effect of mitoxantrone-polybutylcyanoacrylate-nanosperes].
Topics: Animals; Carcinoma, Hepatocellular; Drug Carriers; Drug Delivery Systems; Enbucrilate; Liver Neoplas | 1993 |
[A model of orthotopic transplantation of human hepatoma established in nude mice tumor inhibition studies].
Topics: Animals; Disease Models, Animal; Drug Delivery Systems; Humans; Liver Neoplasms; Mice; Mice, Inbred | 1993 |
Multimodal adjuvant treatment and liver transplantation for advanced hepatocellular carcinoma. A pilot study.
Topics: Adult; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Female; Foll | 1994 |
Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates.
Topics: Animals; Bile; Biotransformation; Carcinoma, Hepatocellular; Cell Line; Cells, Cultured; Chromatogra | 1993 |
[Combined mitoxantrone therapy for heavily pretreated metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Doxor | 1993 |
[Percutaneous drainage of refractory necrotizing tumors: experience in 9 patients].
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Cystadenocarcinoma; Drainage; Female; His | 1995 |
[Effects of intra-hepatic arterial injection of mitoxantrone for hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Carcinoma, Hepatocellular; Drug Administration Sche | 1996 |
[The effect of hepatic arterial infusion chemotherapy on the prognosis after hepatectomy for hepatocellular carcinoma].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Emboliza | 1998 |
[A case of breast cancer with liver metastases responding remarkably to combination therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 1999 |
Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 2000 |
Recurrent gastrointestinal stromal sarcomas.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Humans; Injection | 2000 |
Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Arthralgia; Bone Neoplas | 2001 |
Experience with methotrexate, 5-fluorouracil, and leucovorin (MFL): a first line effective, minimally toxic regimen for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brai | 2002 |
Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors.
Topics: Aged; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Mitoxantrone; P | 1992 |
[Successful preparation of mitoxantrone emulsion containing non-ionic contrast medium].
Topics: Carcinoma, Hepatocellular; Delayed-Action Preparations; Drug Therapy, Combination; Emulsions; Humans | 1992 |
[Liver transplantation associated with combined adjuvant treatment in hepatocellular carcinoma. Feasibility and preliminary results].
Topics: Adult; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Doxorubicin; Embolization, Therapeutic; Fe | 1992 |
Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy.
Topics: alpha-Fetoproteins; Analysis of Variance; Antineoplastic Agents; Ascites; Bilirubin; Carcinoma, Hepa | 1992 |
Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer.
Topics: Adenocarcinoma; Agranulocytosis; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Carriers; | 1992 |
Changes in mode of response to chemotherapy for hepatocellular carcinoma induced by transarterial embolization. A case report.
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Humans; Liver Neopl | 1991 |
Serum and tissue alpha-L-fucosidase activity in the pre-clinical and clinical stages of hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; alpha-L-Fucosidase; Carcinoma, Hepatocellular; Doxorubicin; Female; | 1991 |
Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Drug Evaluation; Female; Hepatitis B; Humans; Liver Neoplasm | 1989 |
The toxicity of menadione and mitozantrone in human liver-derived Hep G2 hepatoma cells.
Topics: Adult; Biotransformation; Carcinoma, Hepatocellular; Cell Survival; Epoxide Hydrolases; Glutathione; | 1989 |
The role of reductive and oxidative metabolism in the toxicity of mitoxantrone, adriamycin and menadione in human liver derived Hep G2 hepatoma cells.
Topics: Carcinoma, Hepatocellular; Doxorubicin; Humans; Liver Neoplasms; Mitoxantrone; Oxidation-Reduction; | 1989 |
Phase II study of mitoxantrone for liver metastases from breast cancer.
Topics: Bone Marrow; Breast Neoplasms; Depression, Chemical; Drug Evaluation; Female; Humans; Infusions, Int | 1989 |
Regional lipiodolized chemotherapy for cholangiocarcinoma associated with oral contraceptives.
Topics: Adenoma, Bile Duct; Adult; Antineoplastic Combined Chemotherapy Protocols; Common Bile Duct Neoplasm | 1987 |
Phase II trial of mitoxantrone in patients with hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Drug Evaluation; Female; Humans; Leukopenia; Liver Neoplasms; Male; | 1988 |
Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study.
Topics: Adult; Aged; Anthraquinones; Carcinoma, Hepatocellular; Child; Drug Evaluation; Female; Heart Diseas | 1985 |
Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Doxorubicin; Female; Hepatic Artery; Humans; Infusions, Intr | 1987 |
[A study of antineoplastic activity of DHAQ on human adenocarcinoma cells of lung hepatoma and gastric cancer cells in vitro].
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Cell Line; Humans; Liver Neoplasms; Lung Neoplasms; Mitot | 1986 |
Phase II trial of mitoxantrone in advanced primary liver cancer: a Cancer and Leukemia Group B Study.
Topics: Adolescent; Adult; Aged; Anthraquinones; Drug Evaluation; Female; Humans; Liver Neoplasms; Male; Mid | 1986 |
Mitozantrone.
Topics: Breast Neoplasms; Humans; Leukemia; Liver Neoplasms; Lymphoma; Mitoxantrone; Neoplasms | 1986 |
Phase II studies of mitoxantrone in patients with primary liver cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Humans; Leukopenia; Liver Neopl | 1985 |